Luveltamab tazevibulin
A folate-receptor ADC designed to work across low and high receptor levels, in a pivotal ovarian cancer trial.
Sutro Biopharma's site-specifically conjugated FRα ADC. Phase 1 showed responses in FRα-low as well as FRα-high tumours; the phase 2/3 REFRαME-O1 trial in platinum-resistant ovarian cancer (any FRα expression >25%) is ongoing, with an interim analysis expected in 2026. Neutropenia and arthralgia are characteristic.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Luveltamab tazevibulin" OR ABSTRACT:"Luveltamab tazevibulin" OR TITLE:"STRO-002" OR ABSTRACT:"STRO-002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Luveltamab tazevibulin, not a curated reading list.